ImmunoPrecise Antibodies Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

ImmunoPrecise Antibodies şirketinin toplam hissedar öz sermayesi CA$32.9M ve toplam borcu CA$2.6M olup, bu da borç-öz sermaye oranını 7.9% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CA$59.3M ve CA$26.4M dir.

Anahtar bilgiler

7.9%

Borç/özkaynak oranı

CA$2.60m

Borç

Faiz karşılama oranı	n/a
Nakit	CA$3.91m
Eşitlik	CA$32.85m
Toplam yükümlülükler	CA$26.45m
Toplam varlıklar	CA$59.30m

Son finansal sağlık güncellemeleri

Recent updates

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Stock's 45% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Nov 24

ImmunoPrecise Antibodies reports FQ1 results

Sep 14

ImmunoPrecise’s polytope program reduces lung inflammation in SARS-CoV-2 challenged hamsters

Jun 17

ImmunoPrecise Antibodies to raise $21.7 via equity offering

Feb 04

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: IPA 'nin kısa vadeli varlıkları ( CA$11.0M ) kısa vadeli yükümlülüklerini ( CA$11.2M ) kapsamıyor.

Uzun Vadeli Yükümlülükler: IPA 'un kısa vadeli varlıkları ( CA$11.0M ) uzun vadeli yükümlülüklerini ( CA$15.3M ) karşılamamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: IPA şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: IPA 'nin borç/öz sermaye oranı son 5 yılda 18.4% seviyesinden 7.9% seviyesine düştü.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: IPA şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: IPA un, serbest nakit akışı her yıl % 27 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

ImmunoPrecise Antibodies Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

ImmunoPrecise Antibodies Receives Nasdaq Notification Regarding Minimum Bid Requirement

ImmunoPrecise Antibodies Announces Voluntary Delisting from TSX Venture Exchange

Recent updates

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Stock's 45% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Immunoprecise Antibodies Ltd. Announces Resignation of Barry A. Springer from Board

Immunoprecise Antibodies Ltd. Announces Significant Breakthrough in Its Primary Cancer Research Initiatives

ImmunoPrecise Antibodies Ltd. Advances Therapeutic Innovation with Rabbit Antibody Developments

ImmunoPrecise Antibodies Ltd., Annual General Meeting, Nov 14, 2024

ImmunoPrecise Antibodies Ltd. to Report Q1, 2025 Results on Sep 16, 2024

ImmunoPrecise Antibodies Receives Nasdaq Notification Regarding Minimum Bid Requirement

Immunoprecise Antibodies Successfully Engineers in Silico Antibodies to Elusive Tumor Protein Using Its Patented LENSai Technology

ImmunoPrecise Antibodies Ltd. announced that it expects to receive CAD 3 million in funding from Yorkville Advisors Global LP

ImmunoPrecise Antibodies Ltd. to Report Fiscal Year 2024 Results on Jul 25, 2024

ImmunoPrecise Antibodies Ltd. Appoints Kristin Taylor as Permanent Chief Financial Officer

Immunoprecise Antibodies Ltd. Announces the Commercial Release of Lens Ai API, Hereafter Referred to as the `Software', by Its Subsidiary, Biostrand

ImmunoPrecise Antibodies Ltd. Announces an Expansion of Its LENSai Platform

ImmunoPrecise Antibodies Ltd. to Report Q3, 2024 Results on Mar 14, 2024

ImmunoPrecise Antibodies Ltd. has filed a Follow-on Equity Offering in the amount of $60 million.

ImmunoPrecise Antibodies Ltd. has completed a Follow-on Equity Offering in the amount of $1.1 million.

ImmunoPrecise Antibodies Ltd. has filed a Follow-on Equity Offering.

ImmunoPrecise Antibodies Ltd. Announces Board Changes

ImmunoPrecise Antibodies Ltd. to Report Q2, 2024 Results on Dec 14, 2023

ImmunoPrecise Antibodies Develops the Lensai's Integrated Intelligence Platform Powered by Hyft Technology

ImmunoPrecise Antibodies Ltd., Annual General Meeting, Nov 09, 2023

ImmunoPrecise Antibodies Announces CFO Transition

ImmunoPrecise Antibodies Ltd. to Report Q1, 2024 Results on Sep 14, 2023

ImmunoPrecise Antibodies Ltd. Announces Board Changes

Ingalls & Snyder Proposes a Change to the Members of ImmunoPrecise Antibodies’ Board

ImmunoPrecise Antibodies Ltd. to Report Q4, 2023 Results on Jul 07, 2023

ImmunoPrecise Antibodies Ltd. Introduces Transformative AI-Driven Rapid Therapeutic Screening Platform

Anna K. Petterson Do Not Act as a Director of ImmunoPrecise Antibodies Ltd

ImmunoPrecise Antibodies Ltd. to Report Q2, 2023 Results on Dec 15, 2022

ImmunoPrecise Antibodies Announces Voluntary Delisting from TSX Venture Exchange

ImmunoPrecise Antibodies Ltd., Annual General Meeting, Dec 13, 2022

ImmunoPrecise Antibodies reports FQ1 results

ImmunoPrecise Antibodies Ltd. to Report Q1, 2023 Results on Sep 14, 2022

ImmunoPrecise Antibodies Ltd. to Report Q1, 2023 Results on Sep 14, 2022

Immunoprecise Antibodies Ltd. Announces the Continuing Success of Polytope® Tatx-03 Antibody Combination Therapy to Neutralize Variants of Concern of the Covid-19 Causative Virus

ImmunoPrecise Antibodies Ltd. Announces Executive Changes

Full year 2022 earnings released: CA$0.85 loss per share (vs CA$0.45 loss in FY 2021)

ImmunoPrecise Antibodies Ltd. to Report Q4, 2022 Results on Jul 29, 2022

ImmunoPrecise Antibodies Ltd. Reports the Critical Third-Party Findings of Two IND-Enabling Pre-Clinical Safety Studies

ImmunoPrecise Antibodies Announces Departure of Stefan Lang, Chief Business Officer

Insider recently bought US$6.8m worth of stock

ImmunoPrecise Antibodies Ltd. Shares Outcome of Recent Laboratory Data on Their PolyTope® TATX-03 Antibody Cocktail

ImmunoPrecise Antibodies Ltd. Releases Data Demonstrating Strong Neutralizing Potency of PolyTope® TATX-03 Antibody Cocktail Towards the SARS-CoV-2 Omicron Variant

ImmunoPrecise Relocates European Subsidiary to LEED Certified Campus to Continue to Advance its Antibody Research Operations and Environmental Sustainability

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Independent Director Brian Lundstrom has left the company

First quarter 2022 earnings released: CA$0.17 loss per share (vs CA$0.037 loss in 1Q 2021)

Full year 2021 earnings released: CA$0.45 loss per share (vs CA$0.36 loss in FY 2020)

ImmunoPrecise Antibodies Ltd. Announces New Results from Its Tatx-03 Polytope™ Therapy

Chief Scientific Officer Yasmina Abdiche has left the company

Chief Scientific Officer Yasmina Abdiche has left the company

Chief Scientific Officer Yasmina Abdiche has left the company

Chief Scientific Officer Yasmina Abdiche has left the company

Chief Scientific Officer Yasmina Abdiche has left the company

Chief Scientific Officer Yasmina Abdiche has left the company

Chief Scientific Officer Yasmina Abdiche has left the company

Chief Scientific Officer Yasmina Abdiche has left the company

Chief Scientific Officer Yasmina Abdiche has left the company

Chief Scientific Officer Yasmina Abdiche has left the company

Chief Scientific Officer Yasmina Abdiche has left the company

Chief Scientific Officer Yasmina Abdiche has left the company

Chief Scientific Officer Yasmina Abdiche has left the company

Chief Scientific Officer Yasmina Abdiche has left the company

ImmunoPrecise Antibodies Ltd. Announces Histopathology Preclinical Data from its Polytopetm Program Confirms Lung Inflammation Reduction

ImmunoPrecise’s polytope program reduces lung inflammation in SARS-CoV-2 challenged hamsters

IMMUNOPRECISE to Present Preclinical Data from ImmunoPrecise's Drug Pipeline During the Bio International Partnering Event

ImmunoPrecise Moves SARS-CoV-2 PolyTope™ Cocktail Program’s Path Toward IND Filing

CEO, President & Director recently bought US$64k worth of stock

Third quarter 2021 earnings released: CA$0.077 loss per share (vs CA$0.046 loss in 3Q 2020)

ImmunoPrecise Antibodies Announces Results from A Comprehensive Screening of 27 Proprietary Anti-SARS-CoV-2 Therapeutic Antibodies

ImmunoPrecise Antibodies Ltd. Announces Data from Preclinical Study of TATX-03 PolyTope Monoclonal Antibody Cocktail Candidate Against Covid-19

ImmunoPrecise Antibodies Ltd. has completed a Follow-on Equity Offering in the amount of $21.739141 million.

ImmunoPrecise Antibodies to raise $21.7 via equity offering